Alchemab Therapeutics
Focus: Alchemab Therapeutics is a UK-based biotechnology company specializing in human-derived antibodies for therapeutic development. The company is at Series A stage, indicating early-stage capital formation and clinical validation.
Profile data last refreshed 8h ago · AI intelligence enriched 1w ago
Funding Stage
SERIES A
Open Jobs
1
Should You Work at Alchemab Therapeutics?
AI assessmentAlchemab is a high-risk, high-uncertainty play suited only for scientists/engineers seeking early-stage platform exposure and equity upside, not stability or near-term career progression.
Why Work Here
- Opportunity to work on differentiated human-derived antibody platform at a foundational stage before clinical expansion
- Entry point into a focused biotech with meaningful IP (5 publications on record) and validated H1B sponsorship capability
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Interview Prep Quick Facts
Help build intelligence for Alchemab Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.